Global miRNA Sequencing and Assay Market Poised for Strong Growth as Genomic Research and Precision Medicine Advance

Global miRNA Sequencing and Assay Market Overview

The Global miRNA Sequencing and Assay Market is expanding as researchers, pharmaceutical companies, and biotechnology organizations increasingly use microRNA analysis to understand gene regulation, disease mechanisms, and potential biomarkers. According to Maximize Market Research, the market was valued at USD 298.51 million in 2022 and is expected to reach USD 702.29 million by 2029, expanding at a CAGR of 13% during 2023–2029. miRNAs are small RNA molecules, generally 21–25 nucleotides long, that regulate protein expression and play important roles in biological processes and diseases, including cancer.

The market's growth is being supported by advances in nucleotide sequencing, increasing genomic research funding, declining sequencing costs, and the growing recognition of miRNAs as disease biomarkers. Their potential applications in cancer research, autoimmune disorders, neurological conditions, drug development, and other areas are increasing demand for sequencing and assay technologies. Next-generation sequencing has also improved sensitivity, throughput, genomic coverage, and the ability to process large numbers of samples simultaneously.

An important opportunity lies in combining miRNA sequencing with multiomics, artificial intelligence, liquid biopsy research, and precision medicine. As researchers seek more comprehensive molecular profiles, sequencing platforms capable of producing high-quality data from small or difficult samples could become increasingly valuable. However, high equipment and infrastructure costs and the shortage of skilled professionals remain challenges for wider adoption.

* Access Exclusive Industry Data: https://www.maximizemarketresearch.com/request-sample/113541/ 

U.S. Market Trends and Investment

North America held the dominant share of the global miRNA Sequencing and Assay Market in 2022, supported by prominent companies, government-backed research, advanced healthcare infrastructure, and strong adoption of sequencing technologies. In 2025, the U.S. life-sciences ecosystem continued to attract substantial investment. Thermo Fisher Scientific announced an additional USD 2 billion investment in the United States over four years, including USD 1.5 billion in manufacturing capital expenditures and USD 500 million in R&D focused on high-impact innovation. The National Institutes of Health also continued substantial biomedical research investment, awarding USD 35.3 billion in competing and noncompeting grants during FY2025. Research specifically targeting circulating miRNAs also received federal support; a 2025 NIH award to Duke University funded development of a highly sensitive miRNA biomarker detection approach for Alzheimer's disease diagnostics. These developments reinforce the U.S. opportunity for advanced sequencing, assay development, biomarker discovery, and precision-medicine applications.

Market Segmentation

According to the supplied MMR report, the market is segmented by Product, Technology, and End Use. Product categories include Library Preparation and Consumables; technology categories include Sequencing by Synthesis, Nanopore, and Ion Semiconductor Sequencing; and end users include Research Institutes, Academia, and CROs.

Within the product segment, Consumables held the largest market share, accounting for 58.9% in 2022. Their dominance is associated with the wider adoption of small-RNA sequencing and recurring requirements for sequencing workflows.

By technology, Sequencing by Synthesis held the largest revenue share at 33.4% in 2022. MMR attributes its strong position to research applications involving miRNA sequencing and its ability to recover interpreted and novel miRNAs.

By end use, Research Institutes dominated with a 56.6% revenue share in 2022, supported by continuing research into miRNA sequencing, drug development, novel drug delivery, and clinical research.

miRNA Sequencing and Assay Market Key Players
1. Illumina Inc.
2. Thermo Fisher Scientific Inc.
3. Qiagen N.V.
4. Takara Bio Inc.
5. New England Biolabs, Inc.
6. Perkinelmer, Inc.
7. Norgen Biotek Corporation
8. Trilink Biotechnologies
9. Lexogen
10.Oxford Nanopore Technologies
11.F. Hoffmann-La Roche Ltd.
12.Bio-Rad Laboratories Inc.
13.Sigma Aldrich Corp.
14.HTG Molecular Diagnostics, Inc.
15.Rosetta Genomics Ltd.
16.Kaneka Corporation
17.Abcam PLC.
18.Meridian Bioscience, Inc
19.System Biosciences LLC

Competitive Analysis

The MMR report identifies Illumina Inc., Thermo Fisher Scientific Inc., Qiagen N.V., Takara Bio Inc., New England Biolabs Inc., PerkinElmer Inc., Norgen Biotek Corporation, Trilink Biotechnologies, Lexogen, Oxford Nanopore Technologies, F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories Inc., Sigma-Aldrich Corp., HTG Molecular Diagnostics, Rosetta Genomics, Kaneka Corporation, Abcam, Meridian Bioscience, and System Biosciences among the key market participants.

The supplied MMR page does not disclose individual company market-share percentages, so an exact ranking of the five companies by global market share would require unsupported assumptions. The following five are therefore discussed as leading/key participants identified by the report rather than as a verified market-share ranking.

Illumina continues to expand sequencing and data-analysis capabilities. In January 2025, Illumina announced a collaboration with NVIDIA combining sequencing technologies, multiomics data, AI, and accelerated computing to improve biological research, drug discovery, and genomic interpretation. Illumina also collaborated with Broad Clinical Labs in 2025 to scale single-cell sequencing research, demonstrating continued investment in high-throughput genomic applications.

Thermo Fisher Scientific maintains extensive miRNA assay capabilities through Applied Biosystems, including TaqMan MicroRNA Assays and high-throughput formats. Its assays are designed for sensitive and specific quantification of mature miRNAs, while its 2025 U.S. investment program strengthens the company's broader R&D and manufacturing infrastructure.

QIAGEN benefits from its molecular-biology and sample-preparation portfolio, positioning the company to serve researchers performing RNA analysis and biomarker discovery. Its broader integration of sample preparation, molecular testing, and bioinformatics supports the increasing need for streamlined genomics workflows.

Takara Bio remains an important participant in molecular biology and sequencing workflows, with opportunities created by growing demand for RNA analysis, library preparation, and high-throughput research applications.

New England Biolabs contributes specialized molecular biology reagents and sequencing-related technologies. Its expertise in enzymes and nucleic-acid research supports researchers developing and optimizing next-generation sequencing workflows.

Across the competitive landscape, the strongest innovation trend is the integration of higher-throughput sequencing, improved sample preparation, AI-enabled analysis, multiomics, and increasingly sensitive biomarker detection.

Regional Analysis

United States: The U.S. is the principal country opportunity within North America, supported by advanced genomic infrastructure, leading sequencing companies, government-funded research, and strong pharmaceutical and biotechnology activity. MMR identifies North America as the dominant regional market.

United Kingdom: The U.K. benefits from an established genomics research ecosystem, academic research institutions, biotechnology activity, and increasing interest in precision medicine and biomarker discovery.

Germany: Germany's strong biomedical research infrastructure and pharmaceutical industry create opportunities for miRNA sequencing and assay technologies, particularly in cancer research and molecular diagnostics.

France: France offers growth opportunities through public research institutions, biotechnology development, and increasing applications of genomics in disease research and personalized medicine.

Japan: Japan's advanced healthcare, biotechnology, and life-sciences industries provide a favorable environment for molecular research. Increasing genomic research and precision-medicine applications support demand for miRNA analysis.

China: China is emerging as an important growth market within Asia Pacific. MMR highlights rapid technological development and expanding genetic research activities in the region, with China receiving increasing attention because of its growing biotechnology and chemical industries.

Conclusion

The Global miRNA Sequencing and Assay Market is projected to grow from USD 298.51 million in 2022 to USD 702.29 million by 2029, representing a 13% CAGR.

In my view, the most significant opportunity will come from the convergence of miRNA sequencing, liquid biopsy research, multiomics, AI-powered genomic analysis, and precision medicine. The increasing use of miRNAs as potential biomarkers creates opportunities beyond basic research, particularly in cancer, neurological diseases, drug discovery, and early disease detection.

Future market growth will depend on making sequencing workflows more sensitive, affordable, scalable, and easier to analyze. Companies that combine advanced sequencing chemistry with automation, high-throughput consumables, sophisticated bioinformatics, and AI-based interpretation will be well positioned to benefit from the next stage of miRNA research and assay development.

About Maximize Market Research

Maximize Market Research Pvt. Ltd. (MMR) is a global market research and consulting firm known for delivering accurate, actionable, and data-driven insights. Our expertise spans diverse industries — including medical devices, pharmaceuticals, technology, automotive, electronics, chemicals, personal care, and consumer goods. We provide services such as market-validated forecasts, competitive intelligence, strategic consulting, and industry impact analysis, helping businesses navigate market complexities and achieve sustainable growth.

Contact Maximize Market Research

MAXIMIZE MARKET RESEARCH PVT. LTD.
2nd Floor, Naval IT Park Phase 3,
Pune-Bangalore Highway, Narhe,
Pune, Maharashtra 411041, India.
📞 +91 9607365656
📧 sales@maximizemarketresearch.com